| Serial Number | 79312182 |
| Word Mark | ELATIVE |
| Filing Date | Wednesday, January 20, 2021 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, March 29, 2022 |
| Registration Number | 6681657 |
| Registration Date | Tuesday, March 29, 2022 |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, January 11, 2022 |
| Goods and Services | Pharmaceutical preparations for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; chemical preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; organic preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; diagnostic preparations for medical use; diagnostic reagents for medical use |
| Goods and Services | Scientific research for medical purposes; pharmaceutical research and development services; conducting clinical trials for pharmaceutical products for others, in particular conducting clinical trials for determining the efficacy and safety of elafibranor; conducting clinical trials for others to determine the efficacy and safety of pharmaceutical products in the treatment of primary biliary cholangitis (PBC); conducting scientific studies and analyses in the field of pharmaceuticals and medicines; scientific research and development, namely, providing information, results and data relating to scientific or medical research and development of pharmaceutical products, via an online searchable database; conducting clinical trials for others; pharmaceutical and biological product development and research services for third parties; conducting clinical research for others; evaluation of the efficacy of pharmaceutical products; clinical product development services |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, June 8, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, June 8, 2021 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | GENFIT |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 33 - NOT AVAILABLE |
| Address | FR |
| Party Name | GENFIT |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 33 - NOT AVAILABLE |
| Address | FR |
| Party Name | GENFIT |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 33 - NOT AVAILABLE |
| Address | FR |
| Event Date | Event Description |
| Thursday, June 3, 2021 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Saturday, June 12, 2021 | APPLICATION FILING RECEIPT MAILED |
| Monday, June 7, 2021 | LIMITATION FROM ORIGINAL APPLICATION ENTERED |
| Tuesday, June 8, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Saturday, August 7, 2021 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Tuesday, August 3, 2021 | ASSIGNED TO EXAMINER |
| Friday, August 6, 2021 | NON-FINAL ACTION WRITTEN |
| Wednesday, August 25, 2021 | REFUSAL PROCESSED BY MPU |
| Wednesday, August 25, 2021 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Saturday, September 11, 2021 | REFUSAL PROCESSED BY IB |
| Monday, December 6, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, December 6, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, December 8, 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, December 9, 2021 | ASSIGNED TO LIE |
| Monday, December 6, 2021 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, January 10, 2022 | NOTIFICATION PROCESSED BY IB |
| Thursday, December 9, 2021 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Wednesday, December 22, 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, December 22, 2021 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, December 22, 2021 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Tuesday, January 11, 2022 | PUBLISHED FOR OPPOSITION |
| Tuesday, January 11, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, March 29, 2022 | REGISTERED-PRINCIPAL REGISTER |
| Sunday, May 8, 2022 | NEW REPRESENTATIVE AT IB RECEIVED |
| Monday, September 12, 2022 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Thursday, June 19, 2025 | NEW REPRESENTATIVE AT IB RECEIVED |
| Tuesday, August 23, 2022 | FINAL DISPOSITION NOTICE SENT TO IB |
| Wednesday, June 29, 2022 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Tuesday, August 23, 2022 | FINAL DISPOSITION PROCESSED |